Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

60 Degrees Pharmaceuticals Says The First Patient Who Completed The Regimen In Expanded Access Study Of Arakoda (Tafenoquine) Combined With Conventional Treatments For Relapsing Babesiosis In Immunosuppressed Patients Has Tested Negative For Babesiosis

Author: Benzinga Newsdesk | October 15, 2025 06:16am

Breakthrough Therapy Designation request has been submitted to FDA
Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA)
Results obtained using highest sensitivity test available; licensed by FDA for blood donation screening
Remaining enrolled patients will complete the study between January and October 2026
Study intended to confirm the high cure rate for tafenoquine in immunosuppressed patients with relapsing babesiosis, as reported by Yale in a 2024 publication

Posted In: SXTP